Published in Int J Cancer on October 15, 2008
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol (2008) 1.59
Microchip-based immunomagnetic detection of circulating tumor cells. Lab Chip (2011) 1.59
Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer (2010) 1.54
Mechanisms of cancer cell metastasis to the bone: a multistep process. Future Oncol (2011) 1.27
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.23
Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications. Pharmacol Ther (2013) 1.15
Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer. Transl Oncol (2013) 1.14
Quantification of rare circulating tumor cells in non-small cell lung cancer by ligand-targeted PCR. PLoS One (2013) 1.04
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol (2011) 1.01
Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol (2012) 0.98
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer (2014) 0.96
Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine (Lond) (2012) 0.87
Nanotheranostics of circulating tumor cells, infections and other pathological features in vivo. Mol Pharm (2013) 0.87
Isolated, disseminated and circulating tumour cells in prostate cancer. Nat Rev Urol (2012) 0.84
Circulating tumour cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancers. Br J Cancer (2012) 0.83
Leukocyte-adjusted epigenome-wide association studies of blood from solid tumor patients. Epigenetics (2014) 0.82
Mutation at the folate receptor 4 locus modulates gene expression profiles in the mouse uterus in response to periconceptional folate supplementation. Biochim Biophys Acta (2013) 0.80
Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential. Mol Diagn Ther (2014) 0.79
Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecol Oncol (2012) 0.79
One-step detection of circulating tumor cells in ovarian cancer using enhanced fluorescent silica nanoparticles. Int J Nanomedicine (2013) 0.78
MINDEC-An Enhanced Negative Depletion Strategy for Circulating Tumour Cell Enrichment. Sci Rep (2016) 0.77
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers. Int J Cancer (2015) 0.77
Conditions associated with circulating tumor-associated folate receptor 1 protein in healthy men and women. PLoS One (2014) 0.77
A Glu-urea-Lys Ligand-conjugated Lipid Nanoparticle/siRNA System Inhibits Androgen Receptor Expression In Vivo. Mol Ther Nucleic Acids (2016) 0.75
Near‑infrared fluorescence imaging of prostate cancer using heptamethine carbocyanine dyes. Mol Med Rep (2014) 0.75
Metastasis and Circulating Tumor Cells. EJIFCC (2012) 0.75
Clinical Significance of Folate Receptor-positive Circulating Tumor Cells Detected by Ligand-targeted Polymerase Chain Reaction in Lung Cancer. J Cancer (2017) 0.75
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Transcription of the dystrophin gene in human muscle and non-muscle tissue. Nature (1988) 7.00
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Screening for ovarian cancer: a pilot randomised controlled trial. Lancet (1999) 5.81
Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A (1998) 4.76
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem (2005) 4.65
Illegitimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci U S A (1989) 4.21
Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res (1974) 3.96
A rare-cell detector for cancer. Proc Natl Acad Sci U S A (2004) 3.95
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res (1992) 3.66
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci U S A (2007) 2.70
Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA (1995) 2.63
Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer (1994) 2.58
Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res (1975) 2.49
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol (1994) 2.25
Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A (1991) 2.16
Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology (2005) 2.15
The folate receptor: what does it promise in tissue-targeted therapeutics? Cancer Metastasis Rev (2007) 1.84
Mouse globin gene expression in erythroid and non-erythroid tissues. Cell (1976) 1.75
Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood (2002) 1.75
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.72
Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol (1995) 1.70
Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci U S A (2006) 1.65
Detection of circulating tumor cells by reverse transcriptase polymerase chain reaction of maspin in patients with breast cancer undergoing conventional-dose chemotherapy. J Clin Oncol (2000) 1.59
Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry (1999) 1.53
Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol (1993) 1.50
Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol (2000) 1.33
Detection of micrometastasis by cytokeratin 20 RT-PCR is limited due to stable background transcription in granulocytes. Br J Cancer (1999) 1.24
CA 125 in benign gynecological conditions. Int J Biol Markers (1999) 1.18
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med (2003) 1.14
Red cell and plasma folate, folate consumption, and the risk of colorectal adenomatous polyps. Cancer Epidemiol Biomarkers Prev (1996) 1.06
The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods. Ann Oncol (1998) 1.06
Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol (1994) 1.04
Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Int J Gynecol Pathol (1991) 1.04
Interference of cytokeratin-20 and mammaglobin-reverse-transcriptase polymerase chain assays designed for the detection of disseminated cancer cells. Med Oncol (2001) 1.03
MECHANISM OF BLOOD-BORNE METASTASES. I. SOME FACTORS AFFECTING LODGMENT AND GROWTH OF TUMOR CELLS IN THE LUNGS. Cancer (1964) 0.97
Quantitative studies on cancer dissemination. Cancer Res (1969) 0.96
Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol Pharm (2007) 0.95
Ovarian endometrioma associated with very high serum CA-125 levels. Chang Gung Med J (2003) 0.90
In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model. Anticancer Res (2005) 0.86
Extremely elevated serum CA125 due to endometriosis. Aust N Z J Obstet Gynaecol (1999) 0.83
Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. Cancer (1999) 0.83
CA-125 concentrations in the serum and pregnancy outcome in IVF cycles. J Assist Reprod Genet (1998) 0.81
[Peri-hepatitis abscess secondary to pelvic peritonitis]. J Gynecol Obstet Biol Reprod (Paris) (2002) 0.80
Not all ovarian cysts in young woman are benign: a case series and review of the management of complex adnexal masses in young women. Aust N Z J Obstet Gynaecol (2006) 0.77
[Benign increase of tumor marker Ca 12-5 in pelvic peritonitis with ascites]. Geburtshilfe Frauenheilkd (1996) 0.77
CA 125 in ovarian cysts, serous effusions and peritoneal washings: immunocytochemical expression. Anticancer Res (1995) 0.77
Detecting Prostate Cancer with Molecular Markers: uPM3. Rev Urol (2005) 0.77
DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med (2006) 7.90
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem (2005) 4.65
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
In vitro and in vivo two-photon luminescence imaging of single gold nanorods. Proc Natl Acad Sci U S A (2005) 3.66
Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med (2008) 3.48
Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med (2003) 3.46
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res (2004) 2.85
The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer. N Engl J Med (2016) 2.72
In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci U S A (2007) 2.70
MR elastography of breast cancer: preliminary results. AJR Am J Roentgenol (2002) 2.65
Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol (2007) 2.58
Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev (2002) 2.56
Mechanisms of the age-associated deterioration in glucose tolerance: contribution of alterations in insulin secretion, action, and clearance. Diabetes (2003) 2.53
Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol (2013) 2.48
Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci (2005) 2.46
Assembly and regulation of a glycolytic enzyme complex on the human erythrocyte membrane. Proc Natl Acad Sci U S A (2005) 2.44
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res (2002) 2.18
Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Physiol Cell Physiol (2004) 2.16
Measurement and quality control issues in multiplex protein assays: a case study. Clin Chem (2009) 2.11
LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer. Clin Chem (2007) 2.09
A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One (2008) 2.09
Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol (2005) 2.09
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol (2013) 2.07
Glucose meter performance criteria for tight glycemic control estimated by simulation modeling. Clin Chem (2010) 2.06
Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol (2008) 2.06
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res (2011) 2.02
Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol (2008) 2.01
Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem (2009) 1.95
Current management strategies for ovarian cancer. Mayo Clin Proc (2007) 1.94
Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. Langmuir (2008) 1.88
B-type natriuretic peptide in the assessment of acute lung injury and cardiogenic pulmonary edema. Crit Care Med (2006) 1.85
Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol (2009) 1.82
Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer (2002) 1.81
Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension (2007) 1.79
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol (2002) 1.79
Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. Arch Intern Med (2006) 1.77
Folate-targeted therapies for cancer. J Med Chem (2010) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Association between mammographic density and age-related lobular involution of the breast. J Clin Oncol (2010) 1.70
Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol (2004) 1.67
Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer (2007) 1.65
Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci U S A (2006) 1.65
ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer (2004) 1.64
Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother (2002) 1.63
Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. J Proteome Res (2007) 1.60
Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev (2004) 1.59
Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev (2004) 1.58
Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev (2008) 1.58
A pilot study of long-acting octreotide for symptomatic malignant ascites. Oncology (2012) 1.56
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res (2006) 1.50
A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood (2008) 1.49
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy. Am J Obstet Gynecol (2004) 1.47
Sixteen-year longitudinal changes in serum prostate-specific antigen levels: the olmsted county study. Mayo Clin Proc (2012) 1.46
Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. Am J Physiol Lung Cell Mol Physiol (2008) 1.46
p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila) (2011) 1.45
Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res (2010) 1.44
Longitudinal changes of benign prostate-specific antigen and [-2]proprostate-specific antigen in seven years in a community-based sample of men. Urology (2012) 1.44
Optimization of laser capture microdissection and RNA amplification for gene expression profiling of prostate cancer. BMC Mol Biol (2007) 1.44
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res (2013) 1.43
Adducin forms a bridge between the erythrocyte membrane and its cytoskeleton and regulates membrane cohesion. Blood (2009) 1.42
A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis. J Biol Chem (2008) 1.41
Category-specific uncertainty modeling in clinical laboratory measurement processes. Clin Chem Lab Med (2013) 1.40
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest (2006) 1.37
Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm (2009) 1.36
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36
Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol (2004) 1.35
Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res (2014) 1.35
Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study. PLoS One (2010) 1.34
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood (2002) 1.34
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res (2006) 1.34
Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Gastroenterology (2012) 1.34
Mammary involution and breast cancer risk: transgenic models and clinical studies. J Mammary Gland Biol Neoplasia (2009) 1.32
Inherited determinants of ovarian cancer survival. Clin Cancer Res (2010) 1.32
Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. Mol Pharm (2009) 1.31
Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res (2012) 1.30
Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum (2002) 1.30
Metastatic renal cell carcinoma to the nose and ethmoid sinus. Urology (2006) 1.30
Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3. Blood (2011) 1.29
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol (2011) 1.28
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer (2008) 1.28
Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett (2004) 1.28
Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.26